---
title: "BIVI: Bezisterim phase II data show significant motor and non-motor benefits and slowed neurodegeneration"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295718009.md"
description: "The SUNRISE-PD phase II trial of bezisterim in early Parkinson's showed significant improvements in both motor and non-motor symptoms, especially in patients with higher baseline inflammation. Biomarker data suggest slowed neurodegeneration, and the drug was well-tolerated, supporting a phase III trial with an enrichment strategy.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-12T22:50:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295718009.md)
  - [en](https://longbridge.com/en/news/295718009.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295718009.md)
---

# BIVI: Bezisterim phase II data show significant motor and non-motor benefits and slowed neurodegeneration

The SUNRISE-PD phase II trial of bezisterim in early Parkinson's showed significant improvements in both motor and non-motor symptoms, especially in patients with higher baseline inflammation. Biomarker data suggest slowed neurodegeneration, and the drug was well-tolerated, supporting a phase III trial with an enrichment strategy.

Based on

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [BIVI.US](https://longbridge.com/en/quote/BIVI.US.md)
- [BIVIW.US](https://longbridge.com/en/quote/BIVIW.US.md)

## Related News & Research

- [BIVI: Bezisterim showed significant clinical and biomarker benefits in early Parkinson's, supporting Phase 3](https://longbridge.com/en/news/295701512.md)
- [BioVie says Phase 2 SUNRISE-PD trial shows bezisterim improves motor and non-motor symptoms in early Parkinson’s disease](https://longbridge.com/en/news/295101020.md)
- [AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline](https://longbridge.com/en/news/296519465.md)
- [Mesoblast completes dosing in Phase 3 rexlemestrocel-L trial for chronic low back pain](https://longbridge.com/en/news/296037778.md)
- [BioVie posts corporate presentation outlining bezisterim, BIV201 clinical programs in neurodegeneration, Long COVID, liver disease](https://longbridge.com/en/news/295220567.md)